Latest Advances

  • Condition: Juvenile Idiopathic Arthritis (JIA)
  • Journal: Acta reumatologica portuguesa
  • Treatment Used: Disease-Modifying Anti-Rheumatic Drugs Discontinuation
  • Number of Patients: 70
  • Published —
This study presented flare rates and remission after disease-modifying anti-rheumatic drugs therapy discontinuation in children with juvenile (of unknown cause) idiopathic arthritis (JIA).
  • Condition: Children Hospitalized with New-Onset Systemic Iuvenile Idiopathic Arthritis (sJIA)
  • Journal: Pediatric rheumatology online journal
  • Treatment Used: First-Line Biologic Initiation
  • Number of Patients: 468
  • Published —
This study determined the effect of early initiation of biologic therapy on glucocorticoid exposure in hospitalized pediatric patients with new-onset systemic juvenile idiopathic (of unknown cause) arthritis (sJIA).
  • Journal: Pediatric rheumatology online journal
  • Published —
Intravenous administration of anakinra in children with macrophage activation syndrome.
  • Journal: Journal of investigative medicine high impact case reports
  • Published —
Macrophage Activation Syndrome in Adults: A Retrospective Case Series.
  • Condition: Children with Juvenile Idiopathic Arthritis
  • Journal: Pediatric rheumatology online journal
  • Treatment Used: Specific Carbohydrate Diet
  • Number of Patients: 22
  • Published —
This study explored the effects of the specific carbohydrate diet in children with juvenile idiopathic (of unknown cause) arthritis.
  • Journal: Pediatric rheumatology online journal
  • Published —
Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
  • Journal: The Turkish journal of pediatrics
  • Published —
Unexpected condition in a rare disease: encephalopathy in early-onset sarcoidosis.
  • Condition: Juvenile Idiopathic Arthritis (JIA)
  • Journal: Arthritis research & therapy
  • Treatment Used: Re-Treatment with Etanercept (ETA)
  • Number of Patients: 1724
  • Published —
This study analyzed the effectiveness of etanercept (ETA) in the re-treatment of juvenile idiopathic arthritis (group of conditions involving joint inflammation; JIA) after a disease flare.
  • Condition: Hepatitis B Virus (HBV)
  • Journal: Advances in rheumatology (London, England)
  • Treatment Used: Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Number of Patients: 605
  • Published —
This study investigated the risk factors for losing hepatitis B virus (HBV) surface antibody in patients with hepatitis B virus surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs (DMARDs).
Showing 1-12 of 92